Leadership
Vertex, Bristol Myers and Regeneron updated investors on launches underway, while Sanofi CEO Paul Hudson assured investors on the late-stage pipeline.
Recent moves in the industry include C-suite and board member changes at MindImmune Therapeutics, plus Heidelberg Pharma gets a new CEO.
If approved, VER-01 would be the first cannabinoid-based therapy for chronic low back pain.
After AI’s magic wand status, it's now come to Google and Open AI CEOs talking of the likelihood of a bubble burst. In this interview, Parexel’s India head discusses how to view returns on such investments, the CRO’s own use cases and the US FDA’s keenness on transparency and open dialogue.
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
Recent moves in the industry include changes at the top at Sonoma Biotherapeutics and Autoimmunity BioSolutions, plus Mosaic Therapeutics gets a new CSO from Karus Therapeutics.
The CEOs of two early-stage biotechs explain to Scrip why investor interest in ocular gene therapies is surging and how they aim to attract big pharma partners.
Meg Alexander is taking the place of founder Jeremy Levin, who is transitioning to executive chair, as Ovid prepares to move lead drug OV329 into a Phase IIa epilepsy study and generate initial data for its first-in-class KCC2 direct activators.
Successful stroke data on the oral Factor XIa inhibitor represents the first Phase III success for the class and is a major boost for Bayer’s cardiovascular franchise.
Leadership, organizational excellence and good old fashioned customer engagement could hold keys to better aligning across go-to-market groups, commercial leaders say.
Recent moves in the industry include new CEO hires at Alpha-9 Oncology, IAMA Therapeutics and Prokarium, plus QurAlis gets a new CMO from AbbVie.
As pressure mounts to cut costs, reduce environmental impact, and accelerate development, pharmaceutical innovators are rethinking how medicines are made. A new generation of technologies—flow chemistry, biocatalysis, high-throughput experimentation (HTE), and advanced automation—is reshaping the fu
CEO Christophe Bourdon tells Scrip that the phone is ringing as the Danish drugmaker aims to become ‘the go-to partner for anything in dermatology.’
Five-year Agamree data shows the novel steroid is a safer and equally effective treatment to standard of care deflazacort or prednisone, the Swiss biotech argues.
Medicxi V marks the venture capital firm's biggest fund till date, raising its tally to six funds in the last decade, totaling over €2bn.
Recent moves in the industry include internal executive changes at Eli Lilly and changes the top at Tahoe Therapeutics, plus Coherus Oncology gets a new chief strategy & corporate affairs officer from Amgen.
Novo Nordisk’s high-dose semaglutide for obesity and Lilly’s oral obesity candidate orforglipron were given priority review vouchers by the US Food and Drug Administration.
Recent moves in the industry include board changes at QuiaPEG Pharmaceuticals, plus Agilent Technologies gets a new CFO from Amgen.
There will be no return to normal for the European biopharma sector which needs to turn increasing macro-pressures into opportunities and become leaner and more efficient, experts at BIO-Europe said this week.
New CEO, Eran Ophir, is banking on positive readouts from AstraZeneca and Arcus’s TIGIT programs soon validating its science as it pushes ahead with its immuno-oncology pipeline in a field littered with disappointments.